Responses
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
